Please find below a link to MSF’s report– released at the AIDS 2018 conference– with latest pricing and an an analysis of access barriers for ARVs and drugs to treat common opportunistic infections.
Stopping senseless deaths
Overcoming barriers to affordable diagnostics & treatments for HIV & opportunistic infections
https://msfaccess.org/stopping-senseless-deaths
The Issue brief provides:
• Analysis access of barriers to affordable, lifesaving diagnostics and treatments for HIV and Ois
• Updated 2018 antiretroviral (ARV) drug pricing information suppliers, and status of 27 drugs/combinations.
• Information on use of dolutegravir (DTG) for use during pregnancy, as second line treatment, and use for children
• Overview of optimal diagnostics and therapies to diagnose and treat opportunistic infections, including TB, cryptococcal meningitis (CM), Pneumocystis pneumonia (PCP), Kaposi sarcoma (KS), severe bacterial infections (SBIs) and cytomegalovirus (CMV)
• Note – since this issue brief was released, drug-resistant TB drug recommendations and prices have changed. See here for MSF’s September letter to J&J, for which we are still waiting a response: https://msfaccess.org/open-letter-jj-calling-affordable-access-critical-tb-drug-bedaquiline
Thanks,
Sharonann
—
Sharonann Lynch
HIV & TB Policy Advisor
MSF Access Campaign